There is growing evidence that virus particles also contain host cell proteins, which provide viruses with certain properties required for entry and release. A proteomic analysis performed on double-gradient-purified hepatitis C virus (HCV) from two highly viraemic patients identified the phosphatidylinositol 3,5-bisphosphate 5-phosphatase FIG4 (KIAA0274) as part of the viral particles. We validated the association using immunoelectron microscopy, immunoprecipitation and neutralization assays in vitro as well as patient-derived virus particles. RNA interferencemediated reduction of FIG4 expression decreased cholesteryl ester (CE) levels along with intraand extracellular viral infectivity without affecting HCV RNA levels. Likewise, overexpressing FIG4 increased intracellular CE levels as well as intra-and extracellular viral infectivity without affecting viral RNA levels. Triglyceride levels and lipid droplet (LD) parameters remained unaffected. The 3,5-bisphosphate 5-phosphatase active site of FIG4 was found to strongly condition these results. Whilst FIG4 was found to localize to areas corresponding to viral assembly sites, at the immediate vicinity of LDs in calnexin-positive and HCV core-positive regions, no implication of FIG4 in the secretory pathway of the hepatocytes could be found using either FIG4-null mice, in vitro morphometry or functional assays of the ERGIC/Golgi compartments. This indicates that FIG4-dependent modulation of HCV infectivity is unrelated to alterations in the functionality of the secretory pathway. As a result of the documented implication of CE in the composition and infectivity of HCV particles, these results suggest that FIG4 binds to HCV and modulates particle formation in a CE-related manner.
INTRODUCTION
Hepatitis C virus (HCV) is a small enveloped positivestrand RNA strand virus and belongs to the genus Hepacivirus in the family Flaviviridae. A hallmark of HCV is its high propensity to establish persistent infection in humans, which in many cases leads to chronic liver disease, cirrhosis and hepatocellular carcinoma (El-Serag, 2012) .
HCV infects hepatocytes and stimulates the accumulation of cholesteryl esters (CE) preferentially in cytoplasmic lipid droplets (LDs). The virus also induces extensive remodelling of endoplasmic reticulum (ER)-derived membranes into a so-called 'membranous web' (Egger et al., 2002) . This web is composed of cholesterol-rich doublemembrane vesicles located in close proximity to LDs, and serves as a site of viral genome replication and particle assembly (Aizaki et al., 2004; Bartenschlager et al., 2011; Paul et al., 2013) . HCV possesses a single RNA molecule which is first translated into a large polyprotein of *3000 aa, and then co-and post-translationally processed into the individual viral proteins by cellular and viral proteinases. Virus particles assemble in an LD-associated subregion of the ER and the Golgi apparatus, and are released via the secretory pathway. However, the precise mechanisms involved in the export process are not yet fully understood. HCV virions incorporate not only viral but also host proteins, many of which have been shown to be functionally implicated in the viral life cycle by modulating cellular processes involved in lipid metabolism (Chang et al., 2007; Huang et al., 2007; Meunier et al., 2008) , protein folding (Parent et al., 2009 ) and others (Benga et al., 2010) .
FIG4 is a phosphoinositide (PI) 59-phosphatase highly specific for phosphatidylinositol 3,5-bisphosphate [PI(3,5)P 2 ] (Tosch et al., 2006) . Mutations in FIG4 lead to neurodegeneration in pale tremor mice and in patients suffering from a specific form of Charcot-Marie-Tooth disease (Chow et al., 2007) , familial epilepsia (Baulac et al., 2014) or Yunis-Varó n syndrome (Campeau et al., 2013) . Altered PI(3,5)P 2 synthesis, turnover and downstream signalling, as well as direct modulation of FIG4, have also been shown to have a profound effect on normal endosomal membrane organization and dynamics (Ikonomov et al., 2006; Michell et al., 2006; Rutherford et al., 2006) .
In this study, we identify FIG4 as a novel component of a significant subset of HCV particles and show that it plays an important role in the HCV life cycle by regulating the levels of CE.
RESULTS AND DISCUSSION

Identification of FIG4 as a HCV virion-associated protein
In order to identify host cell factors that associate with circulating HCV virions, we performed a proteomic analysis of HCV particles isolated from the plasma of two viraemic patients. Plasma from an aviraemic subject served as control. After initial pelleting, HCV particles were sedimented on iodixanol gradients via isopycnic centrifugation. Monitoring HCV RNA in the collected fractions identified peaks of viral RNA at 1.04 and 1.17 g iodixanol ml 21 . To further decrease the level of non-specific background, we subjected our virus-containing fractions to a second iodixanol gradient-based purification step (Parent et al., 2009) . Following HPLC/MS analysis of the virus-containing fractions, we found FIG4 to be significantly enriched in these fractions, but absent from the corresponding aviraemic control samples.
In order to confirm the presence of FIG4 on the particles, we immunoprecipitated FIG4 from infected Huh7.5 cells. We then investigated whether we could enrich these preparations in terms of HCV RNA levels. In order to substantiate our results, we used mouse monoclonal and rabbit polyclonal anti-FIG4 antibodies obtained from two different suppliers. As expected, our positive control, the human anti-E2 CBH5 mAb, showed the highest enrichment ratio when compared with an isotype control (Fig. 1a) . RNA of in vitro-produced HCV from either genotype 1 or 2 could be enriched 1.7-fold (genotype 2) and *30-fold (genotype 1) (Fig. 1b, c) . To confirm these results in a clinical setting, we performed immunoprecipitation/quantitative real-time (qRT)-PCR using doublefractionated patient plasma. We analysed whole plasma as well as low-density lipoviral particles (LVPs, dv1.05) and the pellet obtained after ultracentrifugation (Fig. 1d) . Interestingly, we obtained different enrichment ratios, depending on the fraction analysed and the antibody used for the precipitation. Whilst RNA from high-density material only poorly co-precipitated, viral RNA could be enriched from whole plasma using the rabbit polyclonal antibody. As the rabbit polyclonal antibody binds the N-terminal domain of FIG4, whilst the mouse mAb binds the C-terminal domain of the protein, this suggests that the association of FIG4 with HCV virions is dependent on the overall composition of the viral particles and is likely to be lipid-sensitive.
To provide further evidence that FIG4 is indeed incorporated into HCV virions, we performed immunogold electron microscopy on supernatants of infected Huh7.5 cells. As shown in Fig. 2(a) , no virion-like structures were observed in HCV-negative supernatants. The same was true for HCV-positive samples stained with the secondary antibodies only, ruling out non-specific staining (Fig. 2b) . However, the anti-rabbit secondary antibody produced a weak background labelling of the grid itself (Fig. 2b) . Although labelling was weak, probing HCV-positive supernatants with anti-FIG4 antibodies clearly detected virions 50-70 nm in size, which is characteristic for in vitroderived viral particles (Catanese et al., 2013) (Fig. 2d-f) . Not all virions were found to be FIG4-positive. Whether this is linked to an intrinsic heterogeneity of FIG4 expression from one viral particle to another or to the low labelling yield, a common issue of immunoelectron microscopy, is unknown. Of note, apolipoprotein E staining in the same context resulted in a similar staining yield as FIG4 (Parent et al., 2009 and data not shown).
Next, we sought to investigate the functional role of virionassociated FIG4. To this end, we pre-incubated cell culturederived genotype 2 (genotype 2 HCVcc) virus particles with anti-FIG4 antibodies and measured changes in infectivity by TCID 50 end-point dilution assay. As expected, the human anti-E2 CBH5 mAb drastically reduced HCV infectivity (Fig. S1a , available in the online Supplementary Material). Pre-incubation with anti-FIG4 antibodies significantly inhibited HCV infectivity by 40-50 %, whilst control antibodies had no effect on the virus (Fig. S1b) . To gain insight into the clinical relevance of our results, we tested virions from an additional genotype 1-infected patient, distinct from the material used for the initial MS analysis. As before, immunogold labelling experiments confirmed the association of FIG4 with the serum-derived HCV particles. Despite the low labelling yield, one to several gold particles were observed per virion when incubated with the anti-FIG4 antibodies (Fig. S2) . Interestingly, the size of FIG4-labelled particles of clinical origin was lower than that of their in vitro counterparts.
Taken together, we identified and confirmed FIG4 as a component of a subset of in vitro-as well as patient-derived HCV virions. What is more, FIG4 appears to be exposed on the surface of the virus particle as it is accessible for antibody binding. These results demonstrate that FIG4 associates with HCV virions and may play a moderate role in early interactions of at least a subset of particles with their target cells, as found with other virion-bound proteins (Chang et al., 2007; Parent et al., 2009 ).
FIG4 locates in close proximity to the ER as well as HCV core-positive LDs, and modulates viral morphogenesis and infectivity
To further dissect the role of FIG4 in the viral cycle, we first assessed the effect of reduced FIG4 expression on HCV replication and infectivity. Huh7.5 cells were transfected with two different FIG4-targeting small interfering RNAs (siRNAs) and knockdown efficiency tested by Western blot analysis (Fig. S3a) . siRNA-mediated cytotoxicity was ruled out after performing sulforhodamine and Neutral red assays (Fig. S3b, c) . As shown in Fig. 3(a, d) , FIG4 depletion did not alter intra-and extracellular HCV RNA genotype 2 levels. In contrast, intra-and extracellular HCV infectivity was decreased by up to 60 and 75 %, respectively (Fig. 3b, e) . Similarly, levels of released HCV core were also decreased (Fig. 3f) . In both cases, siRNAmediated inhibition could be largely rescued by the addition of exogenous phosphatidylinositol 3-phosphate (PI3P) (Fig. 3c, g ).
We used the same approach for genotype 1 virus, except that infectivity assays could not be performed due to the low propagation potential of these strains in vitro. Again, whilst FIG4 depletion had no impact on intracellular HCV RNA genotype 1 levels (Fig. 4a) , it did decrease HCV core release in a similar manner as observed for genotype 2 (Fig. 4b) . Taken together, the data suggest that FIG4 is involved in the viral life cycle downstream of the replication phase.
Next, we investigated the effect of FIG4 overexpression on HCV. To this end, we transfected Huh7.5 cells with Cterminal GFP-tagged WT FIG4 or a phosphatase-dead mutant harbouring a C486S point mutation in its catalytic domain. GFP-only served as control plasmid (Fig. S4a) . As for the siRNA oligonucleotides, proper expression and absence of cytotoxic side-effects were verified by Western blot and cell viability assays ( Fig. S4b-d ). Three days after plasmid transfection and virus infection, cells were harvested, and viral replication and infectivity measured as before. In accordance with our previous data, FIG4 overexpression had no significant effect on overall HCV genotype 2 RNA levels ( Fig. 5a , c), whilst a respective fourand sixfold increase of intra-and extracellular HCV infectivity was observed when compared with GFP control cells. Expression of phosphatase-dead FIG4-GFP resulted in a weak, yet not statistically significant increase of HCV intracellular infectivity ( Fig. 5b ) and released HCV core levels ( Fig. 5e ). As shown in Fig. 6 (a, b), similar results were obtained for WT FIG4 and a genotype 1 virus. Surprisingly, phosphatase-dead FIG4 increased HCV core release, although to a lesser extent than the WT construct.
HCVGoat anti-rabbit
Goat anti-mouse Anti-FIG4 sc-98633
Association of FIG4 with cell culture-derived HCV particles. (a-f) Concentrated supernatants of infected Huh7.5 cells were deposited onto grids and processed for immunogold labelling using the indicated primary antibodies. Bound antibodies were detected using secondary antibodies conjugated to 10 nm gold particles. White arrows depict bound gold particles in lower magnification images. Gold particles located j40 nm (corresponding to a single immunoglobulin length) away from the virion were considered specifically bound. Images are representative of two labelling procedures. Bars, 100 nm (a); 50 nm (b-f). Whether this was linked to structural differences in the genotype 1 and genotype 2 core sequences making the former sensitive to FIG4's backbone for morphogenesis is unknown. Taken together, these results further support the role of FIG4 in the formation of functional HCV particles and suggest that the phosphatase activity of FIG4 is involved in the process.
Virion-bound host proteins often contribute to viral budding, not least due to their specific intracellular location. Using immunofluorescence microscopy we studied the association of FIG4-GFP with a set of organelle-and virus-specific markers. As expected, GFP-only produced a diffuse signal in the cytosol and the nucleus (Fig. S5a) . In contrast, we observed a distinct punctate staining pattern for FIG4, which did not change, regardless of the infection status of the cells. Indeed, FIG4 appeared to closely associate with the ER marker calnexin (Fig. 7, top row) and Oil red O-stained LDs (Fig. 7, second row) . However, we could not confirm the previously published localization of FIG4 to early endosomes labelled with EEA1 (Sbrissa et al., 2007) (Fig. S5b) . Given that LDs have been shown to be the site of viral morphogenesis and budding, we next looked at the association of FIG4 with HCV core protein and dsRNA in infected cells. HCV core protein associated with LDs can be easily distinguished by virtue of its characteristic doughnut-shaped staining pattern. Interestingly, FIG4 localized at the immediate vicinity of LD-associated HCV core (Fig. 7, third row) . Likewise, rarer yet visible co-localization was observed between FIG4 and HCV dsRNA complexes (Fig. 7, fourth row) . In summary, we showed that a substantial fraction of the FIG4 cytosolic pool appears to be located around core-decorated ER/LD structures which corresponds to HCV assembly sites (Miyanari et al., 2007) , arguing for a role of FIG4 in the viral budding processes. SAC1 is an ER-membrane-spanning PI phosphatase, which is involved in the HCV secretion process (Bishé et al., 2012) . Interestingly, FIG4 also possesses a catalytic SAC1 domain (Sbrissa et al., 2007) . However, despite this similarity, not much is known about the topology. We thus conducted an in silico analysis of FIG4 using the TMHMM server, TMpred, SPLIT 4.0 server and DAS programs. All four programs identified a potential transmembrane domain ranging from residue 83 to 105. In addition, FIG4 contains a canonical arginine-based RXRXX motif (i.e. RNRYL at positions 903-907) -a known ER transmembrane retention signal. Overall, this suggests that FIG4 is associated with the ER membrane, which would explain how it is incorporated into the virion during assembly and budding.
Several bacteria and viruses modulate and exploit the host PI metabolism to ensure efficient replication and survival (Delang et al., 2012) . Another PI-related enzyme, phosphatidylinositol 4-kinase (PI4KIIIa), has also been demonstrated to be crucial for HCV replication (Berger et al., 2009; Harak et al., 2014; Trotard et al., 2009 ). PI4KIIIa appears to be directly recruited and activated by the HCV non-structural NS5A protein to the replication complexes (Berger et al., 2009) . Other PI-binding proteins with roles in the HCV life cycle include the oxysterol binding protein which is instrumental for HCV secretion that binds phosphatidylinositol 4-phosphate (Amako et al., 2009) , and annexin A2, both of which are required for virus assembly (Backes et al., 2010) . HCV morphogenesis/secretion and replication are often differentially regulated. Until recently, only PI4KIIIa products have been implicated in the viral life cycle. Hence, together with a recently published study indicating that phosphatidylinositol 4,5-bisphosphate mediates viral genome replication (Cho et al., 2015) , our results strengthen the relevance of other, additional species of PIs for HCV propagation. Nicholson et al., 2011) are associated with hepatic defects. Nevertheless, to assess if the FIG4-mediated effect on viral infectivity could be due to modulation of the secretory pathway, we first examined the ultrastructure of hepatocytes from FIG4-null mice by transmission electron microscopy. However, no morphological alterations were observed when compared with WT mice (Fig. S6) . Next, we knocked down FIG4 in Huh7.5 cells and, using immunofluorescence, examined various compartments of the secretory pathway, such as the reticular subdomain of the ER (CLIMP63 staining), the intermediate compartment (ERGIC53 staining) and the Golgi apparatus (GM130 staining). However, as shown in Fig. S6 , no noticeable differences were observed. Next we used a so-called RUSH (retention using selective hooks) assay (Boncompain & Perez, 2013) to test the functionality of the secretory pathway. As before, depletion of FIG4 did not impair the trafficking of secretory cargo between the ER and the Golgi (Fig. S7-S9 ). Taken together, these results suggest that FIG4 modulates infectivity through distinct processes other than secretion.
FIG4, CE levels and the secretory pathway
Given the interplay between PIs and lipids, their previous association with the HCV life cycle, and our observed FIG4-dependent HCV phenotype, we tested if FIG4 could modulate triglyceride (TG) and CE levels, two of the main classes of lipids hijacked by HCV for its own replicative benefit (Alvisi et al., 2011) . TG levels and LD volume and numbers remained unaffected by FIG4 knockdown or overexpression (not shown). In contrast, FIG4 depletion reduced cellular CE levels two-to threefold (Fig. 8a) , whilst FIG4 overexpression resulted in a two-to three-fold CE increase (Fig. 8b ) in naive as well as HCV-infected Huh7.5 cells (Fig. 8c, d) . Interestingly, one of the siRNAs used (targeting exon 19 at the extreme 39 side of the FIG4 transcript) did not exert its effect in HCV-infected cells (Fig. 8c) , suggesting that an isoform expression switch towards an exon 19-negative FIG4 occurred upon infection. Rescue of infectivity by exogenous PI3P upon RNA interference depletion of FIG4 by both siRNAs strengthens this hypothesis and rules out the likelihood of off-target effects as the source of the phenotype observed. Circulating HCV virus particles resemble verylow-density lipoprotein (VLDL)-like particles termed LVPs, which are enriched for CE (Merz et al., 2011) . In addition, HCV infection modulates CE synthesis to facilitate the production of infectious particles. Moreover, inhibition of cholesterol esterification impairs production of infectious virus (Liefhebber et al., 2014; Read et al., 2014) . Together, this suggests that FIG4 might affect viral morphogenesis and secretion by modulating levels of CE. However, the FIG4-induced differences in CE levels are independent of its phosphatase activity, suggesting an additional FIG4 mode of action. One cannot rule out the fact that structural features of FIG4 as an enzymically inert backbone in the case of the phosphatase-dead mutant are sufficient for activation of CE accumulation, whilst the phosphatase activity is necessary for viral infectivity. Also, isoform switches may occur upon HCV infection (Colman et al., 2013) , which could explain the apparent uncoupling of backbone and activity under certain circumstances. As for entry, anti-FIG4 antibodies may either limit access of CE to its receptors (such as SRB1, LDLR or NPC1) through steric hindrance or may directly impede interactions of FIG4 with putative binding partners. The fact that FIG4 has been shown to co-localize with EEA1 in some instances (Sbrissa et al., 2007) could also mean it is involved in post-entry steps at the endosome level. HCV association with FIG4 clearly provides an advantage for virion production, possibly via FIG4-mediated modulation of CE. As mentioned above, the function of FIG4 in the liver is still unknown. To our knowledge it is also not fully understood how to link PI phosphatases to cholesterol metabolism. Nevertheless, an increasing number of reports show that PI-mediated signalling events are at least in some cases cholesterol-dependent. Interestingly, the PTEN phosphatase influences CE levels through its protein phosphatase activity (Peyrou et al., 2013) and FIG4 may stimulate CE synthesis possibly by also acting as a protein phosphatase (Duex et al., 2006) . Given the importance of CE biology in HCV pathophysiology and VLDL formation (Alvisi et al., 2011; Lambert et al., 2013) , future studies aiming at identifying the molecular bases of this finding are certainly needed.
In summary, this study demonstrates that FIG4 (KIAA0274), a recently identified PI phosphatase with a hitherto unknown function in the liver, is an HCV virion component and modulates viral infectivity in a post-replicative fashion, possibly by influencing CE levels.
METHODS
Purification of HCV virions. Clinical material was processed under the approval of the French Institutional Review Board (CPP Sud-Est II; agreement 2010-08-AM2). Infected plasma was obtained from three HCV-positive patients and an aviraemic control, and processed after approval of the French Institutional Review Board (CPP Sud-Est II; agreement 2010-08-AM2). Plasmas were stabilized with 10 mM HEPES (Gibco), antiproteases (Roche), centrifuged at 8000 g for 15 min at 4 uC, filtered through 0.45 mm membranes, layered onto a 20 % sucrose cushion in TNE (10 mM Tris/150 mM NaCl/2 mM EDTA) and ultracentrifuged at 27 000 r.p.m. in a Beckman SW32Ti rotor for 4 h at 4 uC. Pellets were then resuspended in 1 ml TNE, layered on top of iodixanol gradients and submitted to isopycnic ultracentrifugation for 16 h at 31 200 r.p.m. in a Beckman SW41 rotor at 4 uC. Fractions were then harvested from the top of the gradient. The amount of HCV RNA in each fraction was determined by qRT-PCR. The fractions with the highest RNA content and the corresponding fractions from the uninfected control were pooled and dialysed against TNE overnight at 4 uC. Fractions were then concentrated 10-to 20-fold in YM-3 concentration devices (Centricon), submitted to a second ultracentrifugation step and processed for MS. Low-density material and pelleted material were separated by ultracentrifugation on a 20 % sucrose cushion as mentioned above. Electron microscopy. Viral suspensions were generated from infected cell supernatants or patient plasma which was clarified and then concentrated on a 20 % sucrose cushion as described previously (Parent et al., 2009) . Suspensions were adsorbed on 200 mesh nickel grids coated with Formvar-C for 2 min at room temperature. Immunogold labelling was performed by floating the grids on droplets of reactive media. Grids were blocked in 1 % BSA/1 % normal goat serum/50 mM Tris/HCl, pH 7.4 for 10 min at room temperature. Incubation with anti-FIG4 primary antibodies (40 mg ml
21
) was carried out in a wet chamber for 2 h at room temperature. Following successive washes in 50 mM Tris/HCl, pH 7.4 and 8.2 at room temperature, grids were first incubated in 1 % BSA/50 mM Tris/HCl, pH 8.2 in a wet chamber for 10 min at room temperature and then labelled with 10 nm gold-conjugated IgG (Aurion) diluted 1/80 in 1 % BSA/50 mM Tris/HCl, pH 8.2 for 45 min. Grids were then subjected to two washes in 50 mM Tris/HCl, pH 8.2 and 7.4, and finally rinsed in distilled water. Following a 2 min fixation with 4 % glutaraldehyde, grids were stained with 2 % phosphotungstic acid for 2 min, and then analysed using a transmission electron microscope (JEOL 1400 JEM) equipped with a Gatan camera (Orius 600) and Digital Micrograph Software. Mouse work was carried out in agreement with the Institutional Review Board of the University of Michigan, using liver pieces derived from other research programmes. For standard ultrastructural analysis by electron microscopy, cells were treated as described previously (Hourioux et al., 2007) .
Immunofluorescence. Plasmid or siRNA-transfected Huh7.5 cells were first stained with the primary antibodies [anti-calnexin (Santa Cruz), anti-HCV core C7/50 (Santa Cruz), anti-dsRNA (Scicons) and anti-EEA1 (BD Biosciences); all used at a concentration of 2 mg ml 21 ] and then incubated with Alexa Fluor 680-conjugated secondary antibodies (4 mg ml
). GFP was detected through direct excitation. LDs were stained using the neutral lipid-specific dye Oil red O. Cell nuclei were counterstained with Hoechst 33358 and visualized under a Leica SP5 confocal microscope. Merged images were obtained using ImageJ (http://imagej.nih.gov/ij/).
Cell culture and HCV infection. The human hepatoma cell line Huh7.5 was cultured in Dulbecco's minimal essential medium (DMEM; Life Technologies) supplemented with 10 % FBS (Thermo Scientific) and 1 % penicillin/streptomycin (Life Technologies).
Viral stocks were generated via transfection of in vitro transcripts encoding the JFH1 genotype 2a-derived strain (Delgrange et al., 2007) . Samples of 2|10 4 cells cm 22 were infected with HCV JFH1 at m.o.i. 0.1. HCV genotype 1 RNA derived from H77 and N strains was electroporated as described previously (Blight et al., 2002) .
Immunoprecipitation and neutralization assays. Supernatants from infected cells were harvested 4 days post-infection, cleared by centrifugation, and then supplemented with 10 mM HEPES and protease inhibitors. Immunoprecipitation of secreted virions with antibodies coupled to protein G magnetic beads (2 mg per immunoprecipitation) was carried out as described previously (Jammart et al., 2013) . Material was then subjected to RNA extraction (Qiagen) and qRT-PCR. For neutralization assays, supernatants from infected cells were harvested 4 days post-infection and then incubated overnight with anti-FIG4 sc-98633 (Santa Cruz), anti-FIG4 N202/7 (Neuromab), anti-HCV E2 clone CBH5, an isotype-matched anti-R04 control antibody (both obtained from S. Foung, Stanford University School of Medicine), or rabbit and mouse immunoglobulins (Sigma) at a final concentration of 0.4, 2 or 10 mg ml 21 (except for anti-HCV E2 antibody, which was used at a final concentration of 0.02, 0.1 or 0.5 mg ml 21 ). Infection of naive Huh7.5 cells seeded the day before at a density of 20 000 cells cm -2 was performed for 3 days. An HCV infectivity assay was then performed.
HCV infectivity assay. Cells were seeded in 96-well plates (6400 per well) the day before infection. Cells were then inoculated with 10-fold serial dilutions of the supernatants of interest. At 96 h post-infection, cells were washed with PBS, fixed for 10 min in methanol/acetone and blocked for 30 min in 1| PBS/5 % BSA. Cells were then probed with in-house HCV antiserum (1/500) in 1| PBS/3 % BSA for 1 h at room temperature. After three washes in 1| PBS/3 % BSA, bound primary antibodies were probed with goat anti-human Alexa Fluor 488 secondary antibodies (1 mg ml
; Life Technologies) for 1 h at room temperature and visualized by epifluorescence (Nikon TE2000E). Viral titres were determined using the adapted ReedMünch method (Lindenbach, 2009 ).
Cloning of FIG4 constructs. The full-length FIG4 ORF (GenBank accession number NM_014845.5) was inserted into the pcDNA3 backbone in-frame with a C-terminal GFP tag using a restriction/ ligation reaction of Sac II and Age I sites. The same strategy was used for the phosphatase-dead mutant bearing the C486S mutation (a gift from M. Meisler, University of Michigan). Final plasmids were verified by sequencing.
FIG4 overexpression and siRNA-mediated knockdown. Subconfluent Huh7.5 cells were transferred to an electroporation cuvette (GenePulser Xcell Electroporation System; Bio-Rad) and then mixed with either 10 mg plasmid DNA or 8 nM siRNA [NT siRNA, siRNA FIG4 #5 (Hs_KIAA0274_5 from Qiagen), siRNA FIG4 #6 (Hs_KIAA0274_6 from Qiagen)]. Cells were then electroporated with one pulse at 140 V, 125 V and 2300 mF. After electroporation, cells were allowed to recover at room temperature for 5 min, and then resuspended in complete DMEM and plated in six-well plates. For the siRNA rescue experiment, 5 mM PI3P (Sigma) was added to the cells.
HCV core protein quantification. HCV core concentration in the supernatant of infected cells was quantified using a QuickTiter HCV Core Antigen ELISA kit (Cell Biolabs).
Neutral red assay. The NR stock solution (40 mg Neutral red dye in 10 ml PBS) was diluted in culture medium to a final concentration of 4 mg ml 21 and then centrifuged at 600 g for 10 min to remove any precipitated dye crystals. Cells were then incubated with 100 ml NR medium for 1 h. NR medium was removed and the cells washed with PBS. Plates were incubated for 10 min under shaking with 150 ml per well of NR destain solution (50 % ethanol 96 %, 49 % deionized water, 1 % glacial acetic acid). OD 540 was measured in a microplate spectrophotometer.
Sulforhodamine assay. Cells were incubated with 100 ml of 0.057 % sulforhodamine at room temperature for 30 min and then rinsed four times with 1 % acetic acid, followed by four washes with distilled water. Plates were left to dry at room temperature and then incubated in 200 ml 10 mM Tris, pH 10.5. Plates were placed on an orbital shaker for 5 min and OD 510 measured in a microplate reader.
qRT-PCR. Total RNA was extracted using TRIzol (Invitrogen). RNA (1 mg) was DNase I-digested (Promega) and then reverse transcribed using M-MLV Reverse Transcriptase (Invitrogen) according to the manufacturer's instructions. qRT-PCR was performed on a LightCycler 480 device (Roche) using iQ SYBR Green Supermix (Bio-Rad). PCR primer sequences and qRT-PCR conditions are reported in Table S1 .
CE quantification. Cells were harvested 3 days after transfection and CE amounts were analysed using a CE quantification kit (Calbiochem).
